PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock

Delisted

PHAS was delisted on the 2nd of November, 2022.

58 hedge funds and large institutions have $53M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
58
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$239K
Puts
$1K
Net Calls
Net Calls Change

Top Buyers

1 +$371K
2 +$280K
3 +$227K
4
BlackRock
BlackRock
New York
+$197K
5
PTP
Platform Technology Partners
New York
+$162K
Name Holding Trade Value Shares
Change
Change in
Stake
1
$22.3M
2
$5.4M
3
$5.27M
4
$4.42M
5
$4.01M
6
$2.56M
7
$1.08M
8
$934K
9
$779K
10
$706K
11
$556K
12
$474K
13
$472K
14
$429K
15
$371K
16
$365K
17
$332K
18
$280K
19
$227K
20
$218K
21
$187K
22
$161K
23
$146K
24
$138K
25
$137K